Pancuronium


Article Author:
Gyan Das


Article Editor:
Christopher Maani


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
2/12/2019 7:53:44 PM

Indications

Pancuronium bromide is a long-acting, bis-quaternary aminosteroid, non-depolarizing, neuromuscular blocking drug (NMBD) which was first synthesized in 1964 and was found to possess fewer adverse effects with regards to hemodynamic stability and histamine release as compared to the prototypical NMBD, d-tubocurarine.[1][2] After the arrival of intermediate-acting NMBDs such as vecuronium, rocuronium, cisatracurium, and atracurium, the use of pancuronium has fallen out of favor with many clinicians due to its long elimination and context sensitive half time and predominantly renal clearance.

The FDA approved indications for pancuronium are similar to those of other NMBDs and include laryngeal muscle relaxation that facilitates endotracheal intubation, skeletal muscle relaxation to support optimal surgical conditions and exposure, and chest wall and diaphragmatic muscle relaxation to improve thoracic compliance in mechanically ventilated patients.

NMBDs are as an adjunctive therapy which may decrease the inflammatory response associated with acute respiratory distress syndrome and lead to reduced mortality and barotrauma associated with mechanical ventilation; however, the studies which investigated utilized a 48-hour infusion of cisatracurium rather than pancuronium or other NMBDs.[3][4] Pancuronium has also been utilized to prevent shivering during therapeutic hypothermia protocols following cardiac arrest.[5]

Mechanism of Action

Pancuronium, as with other non-depolarizing NMBDs, is a competitive inhibitor at the postjunctional nicotinic acetylcholine (ACh) receptor; normally, the postjunctional ACh receptor in skeletal muscle functions as a ligand-gated ion channel which binds ACh to allow passage of sodium ions to cause depolarization of the cell membrane leading to skeletal muscle contraction. The nicotinic ACh receptor has five subunits; alpha subunits are two of the five subunits and serve as the binding site for ACh and NMBDs. Pancuronium is a steroidal molecule which contains ACh-like moieties, facilitating binding to the alpha subunit. Binding of pancuronium to at least one of the alpha subunits causes a conformational change in the ACh receptor and causes the ion channel to remain closed, preventing ion passage and depolarization. Additionally, pancuronium, owing to its large molecular size when compared to ACh, may physically occlude the ion channel and prevents ion passage; this mechanism of ACh receptor blockade becomes more significant with an increased number of molecules present.

Pharmacokinetically, pancuronium is a highly ionized and water-soluble compound at physiologic pH. Because of the poor lipid solubility of pancuronium, it does not cross the blood-brain barrier to exert central nervous system effects, renal tubular reabsorption is minimal, and does not traverse the placenta with minimal fetal effects. Owing to the pancuronium's poor lipid solubility, the volume of distribution is nearly equivalent to circulating plasma volume. Redistribution and diffusion away from the neuromuscular junction (NMJ) contribute significantly to the clinical characteristics of the drug. Pancuronium gets cleared from the plasma primarily through renal excretion (80%). Hepatic degradation (10%) and biliary excretion (10%) play minor roles in the clearance of this drug. Hepatic deacetylation leads to several inactive metabolites and 3-desacetylpancuronium which exhibits half to two-thirds of the potency of pancuronium at the NMJ; the effect of this metabolite can be clinically significant in renal impairment.

Pharmacodynamically, there are several drugs and clinical situations which may either potentiate or diminish the clinical effect of pancuronium.

Drugs and clinical syndromes which potentiate neuromuscular blockade:

  • Volatile anesthetics
  • Aminoglycoside antibiotics
  • Local anesthetics
  • Cardiac antiarrhythmic drugs
  • Dantrolene
  • Magnesium
  • Lithium
  • Tamoxifen
  • Myasthenia gravis
  • Duchenne muscular dystrophy

Drugs and clinical syndromes which diminish neuromuscular blockade:

  • Calcium
  • Corticosteroids
  • Anticonvulsant drugs
  • Burn Injury
  • Denervation injury
  • Immobility

Administration

Pancuronium administration is by intravenous bolus. A continuous IV infusion may be a consideration in the management of the critically ill patient.

The typical intubating dose is 0.1 mg/kg with a 3 to 5-minute onset to maximal muscle relaxation. The 95% Effective Dose is 0.07 mg/kg. There is a 60 to 90-minute duration of action (return to 25% of control twitches) with a typical intubating dose. Maintenance of neuromuscular blockade can be accomplished with a dose of 0.02 mg/kg, titrated to the level of blockade.

Typical infusion dosing may range from 0.7 to 2 mcg/kg/min.

Adverse Effects

Patients with renal failure may experience a 30 to 50% decrease in plasma clearance of pancuronium and associated prolonged neuromuscular blockade.

Owing to its blockade of muscarinic receptors, mainly M2 receptors found in the atria, pancuronium results in increases in heart rate, mean arterial pressure, and cardiac output.[6]

Pancuronium and other NMBDs have been associated with persistent weakness syndromes in critically ill patients requiring prolonged infusions of these drugs. Critically ill patients have many comorbidities such as acid-base derangements, electrolyte imbalances, and organ system failure which may lead to myopathies and polyneuropathies.[7][8]

It is important to note that pancuronium has no anesthetic, amnestic, or analgesic properties and patients may have intraoperative recall leading to significant morbidity and psychological trauma without the use of sufficient anesthetic agents.

Contraindications

History of hypersensitivity or anaphylactic reaction is an absolute contraindication to the use of pancuronium.

Renal disease is a relative contraindication to the use of pancuronium, especially with other available NMBDs which have decreased or absent renal clearance such as rocuronium, vecuronium, and cisatracurium.

Use of pancuronium should merit careful consideration in cardiac dysfunction, and myocardial disease due to concerns for myocardial ischemia, ventricular ectopy, and cardiovascular collapse secondary to vagolytically mediated tachycardia.[9]

Monitoring

Monitoring of neuromuscular blockade with pancuronium should be through qualitative and/or quantitative peripheral nerve stimulation. Most often, this is accomplished by placement of electrodes overlying the facial nerve on the lateral face, the ulnar nerve at the wrist, or the tibial nerve at the ankle. Supramaximal electrical stimulation produces muscular contraction which may be observed to achieve qualitative evaluation or measured by acceleromyography to achieve quantitative assessment. There are patterns of neural stimulation to monitor neuromuscular blockade including train-of-four (TOF), tetanus, and double burst stimulation (DBS).

Typical TOF stimulation occurs with four electrical impulses at 2 Hz. With each repetitive stimulation in the presence of pancuronium or other nondepolarizing NMBD, ACh is released at the NMJ in diminishing amounts correlating to the decreased amplitude of muscular contraction. The ratio of the first and fourth muscular contraction is measured as the TOF ratio which allows for quantification and estimation of recovery from the neuromuscular blockade. Typical tetanic stimulation occurs with a continuous electrical stimulation at 50 Hz over 5 seconds. Pancuronium and other nondepolarizing NMBD result in a non-sustained or fading, the amplitude of muscular contraction. DBS is characterized by two bursts of three electrical stimuli separated by 750 ms which are recognized clinically as two separated twitches. DBS provides an improved ability to discern deep levels of neuromuscular blockade.[10] Monitoring of neuromuscular blockade is imperative for maintaining appropriate blockade and allowing for recovery from and reversal of blockade at the end of a surgical case.

Enhancing Healthcare Team Outcomes

Recovery from pancuronium can be prolonged compared to other NMBDs. The use of an anticholinesterase drug can help hasten this recovery; neostigmine is a typical drug for reversal of NBMD in the peri-operative setting although edrophonium or pyridostigmine are also options. Reversal of neuromuscular blockade occurs by increasing the ACh available at the NMJ by inhibition of cholinesterase, allowing for ACh to competitively inhibit pancuronium to bind and block the postjunctional receptors. It is critical to note that the administration of anticholinesterase medications may be ineffective with a significant depth of blockade. Anticholinesterase drugs should be administered with anticholinergic drugs to prevent bradycardia in the reversed patient.

Due to the long duration of action of pancuronium, it may be associated with more residual blockade after reversal when compared to intermediate- and short-acting NMBDs.[11]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Pancuronium - Questions

Take a quiz of the questions on this article.

Take Quiz
What is pancuronium?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
After general anesthesia in a patient given pancuronium, which of the following is most often used to reverse its effects?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following antibiotics can prolong the effects of pancuronium in an intubated patient with pneumonia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Pancuronium affects what part of the nervous system?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 36-year-old woman has received pancuronium to facilitate muscle relaxation during abdominal surgery. After surgery, which of the following agents is most appropriate for reversing the neuromuscular block?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
An 81-year-old male with end-stage renal disease undergoes intramedullary nail fixation after suffering from a fall. An intubating dose of pancuronium is given at the start of the case, and paralysis is maintained throughout the case. At the end of the case, the patient is not spontaneously breathing and is not a candidate for reversal based on peripheral nerve stimulation. Which metabolite of pancuronium do you suspect may be contributing to this clinical picture?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Pancuronium - References

References

HEWETT CL,SAVAGE DS,LEWIS JJ,SUGRUE MF, ANTICONVULSANT AND INTERNEURONAL BLOCKING ACTIVITY IN SOME SYNTHETIC AMINO-STEROIDS. The Journal of pharmacy and pharmacology. 1964 Nov;     [PubMed]
Levin N,Dillon JB, Cardiovascular effects of pancuronium bromide. Anesthesia and analgesia. 1971 Sep-Oct;     [PubMed]
Forel JM,Roch A,Marin V,Michelet P,Demory D,Blache JL,Perrin G,Gainnier M,Bongrand P,Papazian L, Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Critical care medicine. 2006 Nov;     [PubMed]
Alhazzani W,Alshahrani M,Jaeschke R,Forel JM,Papazian L,Sevransky J,Meade MO, Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Critical care (London, England). 2013 Mar 11;     [PubMed]
Chamorro C,Borrallo JM,Romera MA,Silva JA,Balandín B, Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: a systematic review. Anesthesia and analgesia. 2010 May 1;     [PubMed]
Murray MJ,DeBlock H,Erstad B,Gray A,Jacobi J,Jordan C,McGee W,McManus C,Meade M,Nix S,Patterson A,Sands MK,Pino R,Tescher A,Arbour R,Rochwerg B,Murray CF,Mehta S, Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Critical care medicine. 2016 Nov;     [PubMed]
Murphy GS, Neuromuscular Monitoring in the Perioperative Period. Anesthesia and analgesia. 2018 Feb;     [PubMed]
Hou VY,Hirshman CA,Emala CW, Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;     [PubMed]
Op de Coul AA,Lambregts PC,Koeman J,van Puyenbroek MJ,Ter Laak HJ,Gabreëls-Festen AA, Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clinical neurology and neurosurgery. 1985;     [PubMed]
Segredo V,Caldwell JE,Matthay MA,Sharma ML,Gruenke LD,Miller RD, Persistent paralysis in critically ill patients after long-term administration of vecuronium. The New England journal of medicine. 1992 Aug 20;     [PubMed]
Hunter JM, Reversal of residual neuromuscular block: complications associated with perioperative management of muscle relaxation. British journal of anaesthesia. 2017 Dec 1;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.